TY - JOUR
T1 - Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers
AU - Lobbes, Marc B. I.
AU - Vriens, Ingeborg J. H.
AU - van Bommel, Annelotte C. M.
AU - Nieuwenhuijzen, Grard A. P.
AU - Smidt, Marjolein L.
AU - Boersma, Liesbeth J.
AU - van Dalen, Thijs
AU - Smorenburg, Carolien
AU - Struikmans, Henk
AU - Siesling, Sabine
AU - Voogd, Adri C.
AU - Tjan-Heijnen, Vivianne C. G.
PY - 2017/4
Y1 - 2017/4
N2 - In this retrospective population-based cohort study, we analyzed breast MRI use and its impact on type of surgery, surgical margin involvement, and the diagnosis of contralateral breast cancer.All Dutch patients with cT(1-4)N(0-3)M(0) breast cancer diagnosed in 2011-2013 and treated with primary surgery were eligible for inclusion. Using multivariable analyses, we analyzed in different categories whether MRI use was related to surgery type, margin involvement, and diagnosis of contralateral breast cancer (CBC).MRI was performed in 10,740 out of 36,050 patients (29.8%). Patients with invasive ductal cancer undergoing MRI were more likely to undergo primary mastectomy than those without MRI (OR 1.30, 95% confidence interval (CI) 1.22-1.39, p <0.0001). Patients with invasive lobular cancer undergoing MRI were less likely to undergo primary mastectomy than those without MRI (OR 0.86, 95% CI 0.76-0.99, p = 0.0303). A significantly lower risk of positive surgical margins after breast-conserving surgery was only seen in patients with lobular cancer who had undergone MRI as compared to those without MRI (OR 0.59, 95% CI 0.44-0.79, p = 0.0003) and, consequently, a lower risk of secondary mastectomy (OR 0.61, 95% CI 0.42-0.88, p = 0.0088). Patients who underwent MRI were almost four times more likely to be diagnosed with CBC (OR 3.55, 95% CI 3.01-4.17, p <0.0001).Breast MRI use was associated with a reduced number of mastectomies and less positive surgical margins in invasive lobular cancer, but with an increased number of mastectomies in ductal cancers. Breast MRI use was associated with a fourfold higher incidence of CBC.
AB - In this retrospective population-based cohort study, we analyzed breast MRI use and its impact on type of surgery, surgical margin involvement, and the diagnosis of contralateral breast cancer.All Dutch patients with cT(1-4)N(0-3)M(0) breast cancer diagnosed in 2011-2013 and treated with primary surgery were eligible for inclusion. Using multivariable analyses, we analyzed in different categories whether MRI use was related to surgery type, margin involvement, and diagnosis of contralateral breast cancer (CBC).MRI was performed in 10,740 out of 36,050 patients (29.8%). Patients with invasive ductal cancer undergoing MRI were more likely to undergo primary mastectomy than those without MRI (OR 1.30, 95% confidence interval (CI) 1.22-1.39, p <0.0001). Patients with invasive lobular cancer undergoing MRI were less likely to undergo primary mastectomy than those without MRI (OR 0.86, 95% CI 0.76-0.99, p = 0.0303). A significantly lower risk of positive surgical margins after breast-conserving surgery was only seen in patients with lobular cancer who had undergone MRI as compared to those without MRI (OR 0.59, 95% CI 0.44-0.79, p = 0.0003) and, consequently, a lower risk of secondary mastectomy (OR 0.61, 95% CI 0.42-0.88, p = 0.0088). Patients who underwent MRI were almost four times more likely to be diagnosed with CBC (OR 3.55, 95% CI 3.01-4.17, p <0.0001).Breast MRI use was associated with a reduced number of mastectomies and less positive surgical margins in invasive lobular cancer, but with an increased number of mastectomies in ductal cancers. Breast MRI use was associated with a fourfold higher incidence of CBC.
KW - Breast cancer
KW - MRI
KW - Lobular cancer
KW - Surgery
KW - Contralateral breast cancer
KW - CONTRALATERAL BREAST
KW - LOCAL RECURRENCE
KW - RE-EXCISION
KW - TUMOR SIZE
KW - CARCINOMA
KW - RISK
KW - THERAPY
KW - METAANALYSIS
KW - MAMMOGRAPHY
KW - FEATURES
U2 - 10.1007/s10549-017-4117-8
DO - 10.1007/s10549-017-4117-8
M3 - Article
C2 - 28132393
SN - 0167-6806
VL - 162
SP - 353
EP - 364
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -